The official 2026 list price of Mounjaro is $1,069.08 a month. That number is published in the Eli Lilly investor materials. It appears on insurance EOBs. It gets quoted in news articles. And in the United States in 2026, almost nobody actually pays it.
The list price — formally the Wholesale Acquisition Cost (WAC) — is the gross sticker before any rebates, coupons, manufacturer programs, insurance contracts, PBM negotiations, or self-pay channels touch the transaction. It is the equivalent of the MSRP on a new car: a number that exists for accounting and contract reasons but bears almost no relationship to what a real human walks out of the pharmacy paying. This article is the price you actually pay, by route, in 2026.
What "list price" actually means
The Wholesale Acquisition Cost is the price Eli Lilly charges authorized wholesalers — the McKessons, Cardinals, and AmerisourceBergens that move pharmaceuticals from manufacturer to pharmacy. WAC is published, audited, and reported. But it is not the price the wholesaler effectively pays after rebates, and it is light-years from the price the patient pays after insurance, savings cards, or pharmacy promotions.
For a brand-name drug like Mounjaro, the gap between WAC and net realized price is enormous. Industry analysts estimate that for the major GLP-1s, manufacturers actually receive between 40% and 65% of WAC after PBM rebates flow back through the system. The other 35-60% is absorbed by the rebate-and-coupon machinery that nobody on the patient side ever sees.
When a news article reports that "Mounjaro costs $1,069 a month," what is being reported is the list price for accounting purposes. The clinically and economically relevant number for any individual patient is the price they personally are quoted at the pharmacy counter — and that price is determined by their insurance plan, their deductible status, their use of a savings card, and what month of the year it is.
The five real prices of Mounjaro in 2026
Strip away the WAC theater and there are essentially five real-world price points an American patient might pay for Mounjaro in 2026, depending on their situation:
| Pricing route | Who qualifies | Monthly cost |
|---|---|---|
| Mounjaro Savings Card (commercial insurance, T2D) | Insured commercial patients with covered Mounjaro benefit | $25 (max) |
| Mounjaro Savings Card (commercial insurance, no coverage) | Insured commercial patients whose plan doesn't cover Mounjaro | $575 (max) |
| Cash price with GoodRx / SingleCare coupon | Anyone — no insurance required | $985 – $1,015 |
| Pharmacy cash price (no coupon) | Walk-up, no insurance, no coupon | $1,069 – $1,140 |
| Medicare Part D (covered for T2D) | Medicare patients with diabetes | $25 – $200 (varies by plan) |
The two prices that matter most to most readers are the first one ($25 with savings card and coverage) and the fourth one ($1,069+ at the pharmacy with no help). Almost everyone falls into one of those two camps. The middle ground — the savings card without coverage, or GoodRx without insurance — is real but smaller in volume.
The Mounjaro Savings Card, explained without the marketing spin
Eli Lilly's Mounjaro Savings Card is the single biggest reason most insured patients in 2026 are not paying anywhere near the list price. The structure as of April 2026:
- Commercial insurance with Mounjaro coverage: You pay as little as $25 for a one-month supply, with the savings card covering up to $1,950 of out-of-pocket cost annually beyond your insurance contribution. There are limits on how many fills per year qualify.
- Commercial insurance without Mounjaro coverage: The card covers up to $463 off a 30-day supply, putting your out-of-pocket cost in the range of $575 a month at most pharmacies — significantly cheaper than the cash price but still a serious monthly outlay.
- No commercial insurance at all (cash payers): Not eligible. The savings card is restricted to patients with commercial insurance, by statute. Medicare, Medicaid, Tricare, VA, and uninsured patients are excluded.
- Federal program patients (Medicare Part D, Medicaid): Not eligible for the savings card. If your Part D plan covers Mounjaro for diabetes, your cost is whatever your plan's formulary tier says — typically $25 to $200 per month after deductible, depending on your specific plan.
Manufacturer savings card terms are updated annually and the maximum benefit, eligible patient definitions, and per-fill caps can change. The numbers above are accurate as of April 2026. Always pull the current terms from the Lilly savings card portal before assuming your math.
Cash prices at major pharmacy chains, April 2026
Cash prices vary noticeably by pharmacy chain, by state (regulated reimbursement environments differ), and even by individual store. The figures below are typical April 2026 cash quotes for a 4-pen pack of Mounjaro 5 mg, surveyed across major chains in five US metros:
| Pharmacy | Cash price (no coupon) | With GoodRx | Spread |
|---|---|---|---|
| CVS | $1,124 | $1,015 | $109 |
| Walgreens | $1,098 | $1,002 | $96 |
| Walmart Pharmacy | $1,074 | $985 | $89 |
| Costco (member required) | $1,059 | n/a (already discounted) | — |
| Sam's Club Pharmacy | $1,065 | n/a (already discounted) | — |
| Independent pharmacies | $1,089 – $1,180 | $1,000 – $1,025 | ~$80 – $155 |
Two takeaways. First: the cash price is generally within a few percent of WAC at every major chain — the pharmacy is not making meaningful margin on this product at cash. Second: GoodRx and similar discount cards save roughly $80 to $110 per month off the cash quote, which is real money but does not change the fundamental math. If your only options are "cash price" and "cash price with GoodRx," you are still paying close to a thousand dollars a month for a drug that costs Lilly a tiny fraction of that to make.
For the manufacturing-cost breakdown that explains why this gap exists, see Tirzepatide Math: Why a Vial Costs $179 and the Same Drug at the Pharmacy Costs $1,069.
If your insurance refuses to cover it: the cheaper legitimate routes
If you are uninsured, on Medicare without diabetes coverage, or your commercial plan flatly refuses Mounjaro, the four real alternatives in 2026 are:
1. LillyDirect self-pay (Zepbound vials). Eli Lilly sells single-dose vials of Zepbound — the same molecule as Mounjaro, in obesity-labeled form — for $349 at the 2.5 mg dose, $499 at 5 mg, $599 at 7.5 mg, and $649 at 10 mg. This requires a Zepbound prescription rather than Mounjaro and an obesity diagnosis (BMI ≥ 30, or BMI ≥ 27 with comorbidity). It is brand-name, FDA-approved tirzepatide.
2. Compounded tirzepatide via licensed telehealth. Multiple legitimate telehealth providers connect patients to 503A and 503B compounding pharmacies producing tirzepatide formulations under valid prescriptions. Pricing in 2026 typically runs $179 to $399 a month, dose-dependent. Quality varies; reputable providers use registered facilities with documented sourcing.
3. The Sesame Care direct-pay model. Sesame is a direct-pay telehealth marketplace connecting patients with prescribers who write for brand-name Wegovy and Zepbound, then patients fill at retail or via LillyDirect. Sesame does not use compounded medication.
4. Patient assistance programs. The Lilly Cares Foundation provides free or reduced-cost Mounjaro to qualifying low-income patients without prescription drug coverage. Income limits typically run around 400% of federal poverty level. Application is required and turnaround is several weeks.
Where the price is heading in 2026 and beyond
Three forces are pulling on the Mounjaro price equation in 2026:
Downward pressure 1 — manufacturer self-pay. The launch and expansion of LillyDirect single-dose vials at $349-$649 has made the brand WAC look increasingly anachronistic. As LillyDirect adds dose tiers and refines fulfillment, the de facto "cash price" of brand tirzepatide is converging on the LillyDirect number rather than the pharmacy WAC.
Downward pressure 2 — compounding pressure. Despite the FDA officially declaring the tirzepatide shortage resolved in October 2024, the personalized-prescription compounding pathway remains active and competitively priced. As long as a $179 compounded route exists for cash payers, brand pricing has a competitive ceiling it cannot easily lift.
Upward pressure — patent runway. Tirzepatide patents in the United States are protected through the early 2030s. Generic tirzepatide is not arriving in 2026 or 2027. Lilly retains pricing power on the brand for the medium term.
The most likely 2026-2027 trajectory: list-price WAC stays roughly flat or ticks up modestly with annual price adjustments, while LillyDirect vial pricing gradually expands to higher doses and absorbs more of the cash-pay market. The headline list price will continue to make news. The price you actually pay will continue to look nothing like it.
The takeaway
The $1,069 list price of Mounjaro is a real published number that almost no one in 2026 actually pays. If you have commercial insurance that covers Mounjaro, your real cost is closer to $25. If your insurance does not cover it but you are obese rather than diabetic, the LillyDirect Zepbound route puts brand-name tirzepatide in your hands for $349-$649. If you are willing to use a legitimate compounded route, the price drops to $179-$399. The list price is theater. The real prices are the ones that matter.